The News

Ablynx identifies novel nanobodies® achieving second milestone in Procter & Gamble collaboration

18/06/2007

GHENT, Belgium, 18 June 2007 - Ablynx, the pioneer in the discovery and development of Nanobodies® has announced that its collaboration agreement with Procter & Gamble Pharmaceuticals Inc. (P&GP), a division of The Procter & Gamble Company, has reached a second milestone. Ablynx has discovered novel Nanobodies® against a second target for possible new treatments in the musculoskeletal area. The first milestone under this collaboration was achieved in December 2006 and was also a target for musculoskeletal diseases.
 
Ablynx's unique and patented Nanobody® technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies® against one of the targets exclusive to the collaboration, triggering a second undisclosed milestone payment.
 
Hennie R. Hoogenboom, PhD, Chief Scientific Officer at Ablynx, said:
"We are delighted to have met another important milestone as part of our on-going collaboration with Procter & Gamble. This is yet another important validation of the speed at which our Nanobody® technology platform can deliver high quality Nanobodies®. We are very excited to advance this programme to the next stage together with Procter & Gamble."
 
Kevin E. Driscoll, PhD, Director New Technology Development at P&GP added:
"We are very pleased with the progression of our collaboration with Ablynx. We are a step closer towards the goal of producing Nanobody® development candidates in this very important area of musculoskeletal diseases."
 
As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies® that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies®, as well as the commercialization of any resulting drug products.
 
 
To open the full PDF version of this press release, please click on the link below:
Press release in PDF format <http://hugin.info/137912/R/1133484/212141.pdf>
<http://hugin.info/137912/R/1133484/212141.pdf> 
 
Contacts:
 
Media Relations for Ablynx:
 
Mary Clark, Director
Capital MS&L
t : +44 (0)20 7307 5336
m: +44 7713 335171
e : mary.clark@capitalmsl.com
 
Halina Kukula
Capital MS&L
t : +44 (0) 20 7307 5340
e: halina.kukula@capitalmsl.com            
 
 At Ablynx:
 
Dr. Edwin Moses
Chairman and CEO
t : +32 (0)9 241 11 51
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
 
Eva-Lotta Allan
Chief Business Officer
t : +32 (0)9 261 06 35
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com <mailto:edwin.moses@ablynx.com>
 
 

Press release in PDF format <http://hugin.info/137912/R/1133484/212141.pdf>